Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paroxetine + sertraline
- Development stage
- Discontinued
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of two selective serotonin reuptake inhibitors (SSRIs) that is not recommended for therapeutic use due to the high risk of serotonin syndrome. Both paroxetine and sertraline individually work by increasing serotonin levels in the brain, but their combined effect can lead to excessive serotonin accumulation and potentially life-threatening adverse effects.
- Brand names
- PaxilZoloftPexeva
- Other names
- Selective Serotonin Reuptake InhibitorsSSRIs
02
Targets
SERT (Sodium-dependent serotonin transporter)
Beyond the preview
Go deeper on paroxetine + sertraline.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paroxetine + sertraline.